Sidley Represents Axsome Therapeutics in its Acquisition of Global Rights to Balipodect from Takeda

Sidley represented Axsome Therapeutics, Inc. (Nasdaq: AXSM), in its acquisition of exclusive global rights from Takeda Pharmaceutical Co. Ltd. to TAK-063 (balipodect), a novel and selective inhibitor for the treatment of schizophrenia and Tourette syndrome. Under the agreement, Takeda received an upfront payment and is eligible to receive royalties and payments related to development, regulatory, and commercial milestones. Axsome plans to begin Phase 3 trial-enabling activities for the schizophrenia indication in 2026.

More information about the transaction is available here.

The Sidley team was led by Adam Welland (Technology and Life Sciences Transactions) as well as Ellen Hunter and Jon Olsen (M&A); and included Torrey Cope (Food, Drug and Medical Device); Sophia Iams (Technology and Life Sciences Transactions); AJ San Diego (M&A); Vadim Brusser (Antitrust and Competition); Jonathan Westreich (Tax); Scott J.F. Goldstein (Insurance); and Sven De Knop and Maryanne Kamau (Global Arbitration, Trade and Advocacy).